Cargando…
Afatinib in advanced NSCLC: a profile of its use
Afatinib [Giotrif(®) (EU); Gilotrif(®) (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases that provides an important first-line treatment option for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutati...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840214/ https://www.ncbi.nlm.nih.gov/pubmed/29540977 http://dx.doi.org/10.1007/s40267-018-0482-6 |